

## Galapagos increases share capital through warrant exercises

**Mechelen, Belgium; 21 October 2013 – Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee and management warrant exercises.**

Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period running from 28 September 2013 through 11 October 2013, Galapagos issued 35,719 new ordinary shares on 21 October 2013 for a total capital increase (including issuance premium) of €242,874.20.

Galapagos' Executive Committee has put a warrant exercise program into place whereby Executive Committee members have made a commitment to exercise a minimum number of warrants during subsequent exercise periods, subject to certain conditions. During this exercise period, three Executive Committee members exercised warrants for a combined total of 15,000 warrants.

To date, Galapagos' total share capital amounts to €161,155,270.61; the total number of securities conferring voting rights is 29,791,021, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,675,296, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

### About Galapagos

[Galapagos](#) (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

AbbVie and Galapagos signed an agreement in CF where they work collaboratively to develop and commercialize oral drugs that address two mutations in the CFTR gene, the G551D and F508del mutation. In the field of inflammation, AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization of [GLPG0634](#) after Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). [GLPG0974](#) is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2 study. [GLPG1205](#) is a first-in-class molecule that targets inflammatory disorders and is currently in a First-in-Human Phase 1 study.

The Galapagos Group, including fee-for-service companies [BioFocus](#), [Argenta](#) and [Fidelta](#), has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: [www.glp.com](http://www.glp.com)

## CONTACT

Elizabeth Goodwin, Director Investor Relations

Tel: +31 6 2291 6240

[ir@glpg.com](mailto:ir@glpg.com)

*This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.*